Immunotherapy for melanoma: The good, the bad, and the future

被引：9
作者：
Poehlein C.H. [1 ]
Rüttinger D. [1 ]
Ma J. [1 ]
Hu H.-M. [1 ]
Urba W.J. [1 ]
Fox B.A. [1 ]
机构：
[1] Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR 97213
来源：
Current Oncology Reports | 2005年 / 7卷 / 5期
关键词：
Melanoma; Treg Cell; Adoptive Transfer; Antitumor Immune Response; Adoptive Immunotherapy;
D O I：
10.1007/s11912-005-0066-1
中图分类号：
学科分类号：
摘要：
The past 20 years have seen remarkable advances in our understanding of the molecular and cellular processes controlling the development of an anticancer immune response. These advances have spawned a renaissance in the field of cancer immunotherapy, the original targeted therapy, during which investigators have pushed the envelope and translated promising strategies into investigational therapeutics in patients with cancer. An approach that combined nonmyeloablative lymphodepleting chemotherapy with adoptive transfer of tumor-specific CD4 and CD8 T cells exhibited an initial objective response rate of 51% for patients with stage IV melanoma. Although this strategy is extremely challenging, one can expect technological advances that may simplify this approach and further improve outcome. Copyright © 2005 by Current Science Inc.
引用
收藏
页码：383 / 392
页数：9
相关论文
共 68 条
[1]  
Speiser D.E., Lienard D., Rufer N., Et al., Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909, J. Clin. Invest., 115, pp. 739-746, (2005)
[2]  
Ray C.M., Kluk, Grin C.M., Grant-Kels J.M., Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream, Int. J. Dermatol., 44, pp. 428-434, (2005)
[3]  
Watts T.H., Tnf/Tnfr family members in costimulation of T cell responses, Annu. Rev. Immunol., 23, pp. 23-68, (2005)
[4]  
Greenwald R.J., Freeman G.J., Sharpe A.H., The B7 family revisited, Annu. Rev. Immunol., 23, pp. 515-548, (2005)
[5]  
Melero I., Shuford W.W., Newby S.A., Et al., Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors, Nat. Med., 3, pp. 682-685, (1997)
[6]  
May Jr. K.F., Chen L., Zheng P., Liu Y., Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells, Cancer Res., 62, pp. 3459-3465, (2002)
[7]  
Strome S.E., Martin B., Flies D., Et al., Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma, J. Immunother., 23, pp. 430-437, (2000)
[8]  
Weinberg A.D., Rivera M.M., Prell R., Et al., Engagement of the OX-40 receptor in vivo enhances antitumor immunity, J. Immunol., 164, pp. 2160-2169, (2000)
[9]  
Kjaergaard J., Tanaka J., Kim J.A., Et al., Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth, Cancer Res., 60, pp. 5514-5521, (2000)
[10]  
Kjaergaard J.L., Peng P.A., Cohen J.A., Et al., Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor, J. Immunol., 167, pp. 6669-6677, (2001)
1234567